Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.20
DVA's Cash-to-Debt is ranked lower than
67% of the 257 Companies
in the Global Medical Care industry.

( Industry Median: 0.40 vs. DVA: 0.20 )
Ranked among companies with meaningful Cash-to-Debt only.
DVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.12 Max: N/A
Current: 0.2
Equity-to-Asset 0.27
DVA's Equity-to-Asset is ranked lower than
81% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 0.47 vs. DVA: 0.27 )
Ranked among companies with meaningful Equity-to-Asset only.
DVA' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.35  Med: 0.25 Max: 0.7
Current: 0.27
-0.35
0.7
Interest Coverage 5.81
DVA's Interest Coverage is ranked lower than
69% of the 216 Companies
in the Global Medical Care industry.

( Industry Median: 8.17 vs. DVA: 5.81 )
Ranked among companies with meaningful Interest Coverage only.
DVA' s Interest Coverage Range Over the Past 10 Years
Min: 2.87  Med: 4.46 Max: 5.81
Current: 5.81
2.87
5.81
Piotroski F-Score: 7
Altman Z-Score: 2.13
Beneish M-Score: -2.73
WACC vs ROIC
6.35%
13.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 16.27
DVA's Operating Margin % is ranked higher than
66% of the 255 Companies
in the Global Medical Care industry.

( Industry Median: 7.71 vs. DVA: 16.27 )
Ranked among companies with meaningful Operating Margin % only.
DVA' s Operating Margin % Range Over the Past 10 Years
Min: 8.49  Med: 15.37 Max: 17.15
Current: 16.27
8.49
17.15
Net Margin % 8.28
DVA's Net Margin % is ranked higher than
58% of the 256 Companies
in the Global Medical Care industry.

( Industry Median: 4.84 vs. DVA: 8.28 )
Ranked among companies with meaningful Net Margin % only.
DVA' s Net Margin % Range Over the Past 10 Years
Min: 1.96  Med: 6.54 Max: 8.28
Current: 8.28
1.96
8.28
ROE % 25.47
DVA's ROE % is ranked higher than
77% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 9.89 vs. DVA: 25.47 )
Ranked among companies with meaningful ROE % only.
DVA' s ROE % Range Over the Past 10 Years
Min: 5.37  Med: 19.11 Max: 25.64
Current: 25.47
5.37
25.64
ROA % 6.53
DVA's ROA % is ranked higher than
51% of the 259 Companies
in the Global Medical Care industry.

( Industry Median: 4.66 vs. DVA: 6.53 )
Ranked among companies with meaningful ROA % only.
DVA' s ROA % Range Over the Past 10 Years
Min: 1.49  Med: 4.95 Max: 6.53
Current: 6.53
1.49
6.53
ROC (Joel Greenblatt) % 72.91
DVA's ROC (Joel Greenblatt) % is ranked higher than
78% of the 257 Companies
in the Global Medical Care industry.

( Industry Median: 21.13 vs. DVA: 72.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DVA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 38.04  Med: 56.82 Max: 72.91
Current: 72.91
38.04
72.91
3-Year Revenue Growth Rate 9.50
DVA's 3-Year Revenue Growth Rate is ranked higher than
56% of the 183 Companies
in the Global Medical Care industry.

( Industry Median: 8.50 vs. DVA: 9.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DVA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.8  Med: 12.7 Max: 44.8
Current: 9.5
4.8
44.8
3-Year EBITDA Growth Rate 9.70
DVA's 3-Year EBITDA Growth Rate is ranked higher than
53% of the 161 Companies
in the Global Medical Care industry.

( Industry Median: 8.10 vs. DVA: 9.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DVA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -38.6  Med: 15 Max: 98.2
Current: 9.7
-38.6
98.2
3-Year EPS without NRI Growth Rate 14.10
DVA's 3-Year EPS without NRI Growth Rate is ranked higher than
60% of the 139 Companies
in the Global Medical Care industry.

( Industry Median: 8.40 vs. DVA: 14.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DVA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -29  Med: 14.1 Max: 125.5
Current: 14.1
-29
125.5
GuruFocus has detected 3 Warning Signs with DaVita Inc $DVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DVA's 30-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

DVA Guru Trades in Q2 2016

Ray Dalio 75,970 sh (+1051.06%)
Andreas Halvorsen 4,611,729 sh (+164.36%)
Jim Simons 1,376,800 sh (+26.14%)
Warren Buffett 38,565,570 sh (unchged)
Joel Greenblatt Sold Out
Mario Gabelli 40,363 sh (-2.89%)
Manning & Napier Advisors, Inc 1,375,595 sh (-28.03%)
Arnold Van Den Berg 79,300 sh (-75.89%)
» More
Q3 2016

DVA Guru Trades in Q3 2016

Joel Greenblatt 45,595 sh (New)
Warren Buffett 38,565,570 sh (unchged)
Andreas Halvorsen Sold Out
Manning & Napier Advisors, Inc 1,354,745 sh (-1.52%)
Arnold Van Den Berg 77,285 sh (-2.54%)
Jim Simons 1,313,500 sh (-4.60%)
Ray Dalio 65,300 sh (-14.05%)
Mario Gabelli 32,613 sh (-19.20%)
» More
Q4 2016

DVA Guru Trades in Q4 2016

Richard Pzena 3,327 sh (New)
Steven Cohen 283,200 sh (New)
Joel Greenblatt 440,617 sh (+866.37%)
Ray Dalio 88,244 sh (+35.14%)
Warren Buffett 38,565,570 sh (unchged)
Arnold Van Den Berg Sold Out
Mario Gabelli 21,663 sh (-33.58%)
Jim Simons 844,500 sh (-35.71%)
Manning & Napier Advisors, Inc 288,580 sh (-78.70%)
» More
Q1 2017

DVA Guru Trades in Q1 2017

Paul Tudor Jones 461,620 sh (New)
Leucadia National 7,135 sh (New)
Andreas Halvorsen 381,597 sh (New)
Ray Dalio 142,304 sh (+61.26%)
Jim Simons 1,192,900 sh (+41.26%)
Mario Gabelli 22,163 sh (+2.31%)
Warren Buffett 38,565,570 sh (unchged)
Richard Pzena 3,327 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt 357,208 sh (-18.93%)
Manning & Napier Advisors, Inc 172,000 sh (-40.40%)
» More
» Details

Insider Trades

Latest Guru Trades with DVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621492    SIC: 8092
Compare:NYSE:UHS, OTCPK:IHHHF, OTCPK:RMSYF, NAS:WOOF, OTCPK:SKHCY, NYSE:EVHC, OTCPK:CAKFF, NYSE:MD, NYSE:HLS, NAS:ACHC, NYSE:CHE, NAS:LPNT, OTCPK:LTGHY, NAS:SCAI, NAS:AMED, NYSE:SEM, NYSE:AMN, NYSE:THC, NAS:TVTY, NYSE:CYH » details
Traded in other countries:TRL.Germany,
Headquarter Location:USA
DaVita Inc, formerly DaVita HealthCare Partners Inc operates kidney dialysis centers and provides related lab services in dialysis centers and in contracted hospitals across USA. It also operates other ancillary services and strategic initiatives.

DaVita is the dialysis provider, with its 2,400 clinics based in the U.S. The company treats nearly 200,000 patients with end-stage renal disease. In a 2012 deal valued at nearly $4.4 billion, DaVita merged with HealthCare Partners, one of the physician group managers in the U.S., which now represents approximately 25% of consolidated revenue. HCP coordinates care for nearly 800,000 members with a network of thousands of physicians and specialists in California, Florida, Nevada, New Mexico, and Arizona.

Top Ranked Articles about DaVita Inc

Paul Tudor Jones’ Top 4 Health Care Buys Guru invested in multiple health care stocks in 1st quarter
Paul Tudor Jones (Trades, Portfolio)’ Tudor Investment Corp. gained 325 new holdings during the first quarter. Among his purchases were multiple health care stocks including VCA Inc. (NASDAQ:WOOF), DaVita Inc. (NYSE:DVA), Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) and Edwards Lifesciences Corp. (NYSE:EW). Read more...
Physicians Dialysis Acquires Seven Dialysis Facilities in New Jersey and Texas
Safirstein Metcalf LLP:  DaVita, Inc. Misled Shareholders According to a Recently Filed Action - DVA
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against DaVita Inc. (DVA) & Lead Plaintiff Deadline - April 3, 2017

NEW YORK, March 30, 2017 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against DaVita Inc. (“DaVita” or the “Company”) (:DVA) and certain of its officers, on behalf of a class who purchased DaVita securities between August 5, 2015 and October 21, 2016, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/dva.  
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into needless insurance plans to maximize profits; (2) DaVita was using American Kidney Fund to facilitate these inappropriate practices; (3) therefore, DaVita’s revenues and profits were illegally acquired; (4) as a result, DaVita lacked effective internal controls over financial reporting; and (5) consequently, DaVita’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis. Once true details were made known to the investing public, the lawsuit claims that investors suffered damages. A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/dva or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in DaVita you have until April 3, 2017 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

Read more...
DEADLINE MONDAY: Lundin Law PC Announces Securities Class Action Lawsuit against DaVita Inc. and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, March 30, 2017 (GLOBE NEWSWIRE) -- Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against DaVita Inc. (“DaVita” or the “Company”) (:DVA) concerning possible violations of federal securities laws between August 5, 2015 and October 21, 2016 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the April 3, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected]. No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member. According to the complaint, during the Class Period, DaVita made false and/or misleading statements and/or failed to disclose: that the Company purposefully steered patients into unnecessary insurance plans in order to maximize profits; that DaVita was using the American Kidney Fund as a vehicle to facilitate these improper practices; that the Company’s revenues and profits were illegally obtained; that DaVita lacked effective internal controls over financial reporting; and that as a result of the above, the Company’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis. When this news reached the public, the stock price of DaVita fell, causing investors harm. Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]
http://lundinlawpc.com/

Read more...
DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In DaVita Inc. To Contact The Firm

STEVENSON, Md., March 29, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of purchasers of DaVita Inc. (:DVA) (“DaVita” or the “Company”) securities during the period between August 5, 2015 and October 21, 2016, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until April 3, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in DaVita securities during the Class Period.  Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company and senior officers steered patients into unnecessary insurance plans to maximize profits; the Company was using the American Kidney Fund as a vehicle to facilitate the improper practices; and, the Company’s revenues and profits were illegally obtained and it lacked effective internal controls over financial reporting. According to the complaint, following a July 1, 2016 filing of a lawsuit by UnitedHealth against American Renal for fraud, an August 8, 2016 announcement slashing the Company’s operating income guidance, August 18, 2016 news reports regarding requests for information to the Company, and an October 23, 2016 article disclosing that DaVita encouraged low-income patients to enroll in commercial plans, the value of DaVita shares declined significantly. If you have suffered a loss in excess of $100,000 from investment in DaVita securities purchased on or after August 5, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html.  You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.  Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others. Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]

Read more...
DVA INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving DaVita Inc. and a Lead Plaintiff Deadline of April 3, 2017

NEW YORK, March 28, 2017 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Colorado on behalf of investors who purchased DaVita Inc. (:DVA) securities between August 5, 2015 and October 21, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/davita-inc. There is no cost or obligation to you. According to the complaint, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into needless insurance plans to maximize profits; (2) DaVita was using American Kidney Fund to facilitate these inappropriate practices; (3) therefore DaVita’s revenues and profits were illegally acquired; (4) as a result, DaVita lacked effective internal controls over financial reporting. On January 6, 2017, the Wall Street Journal published an article revealing that DaVita had received subpoenas from federal prosecutors seeking “the production of information related to charitable premium assistance” in connection with DaVita’s ties to the American Kidney Fund, a charity that helps patients pay for kidney dialysis. If you suffered a loss in DaVita you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/davita-inc. Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

Read more...
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In DaVita Inc. To Contact The Firm

NEW YORK, March 27, 2017 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in DaVita Inc. (“DaVita” or the “Company”) (:DVA) of the April 3, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers. The lawsuit has been filed in the U.S. District Court for the District of Colorado on behalf of all those who purchased DaVita securities between August 5, 2015 and October 21, 2016 (the “Class Period”).  The case, Peace Officers’ Annuity and Benefit Fund of Georgia v. DaVita Inc. et al., No. 1:17-cv-00304 was filed on February 1, 2017, and has been assigned to Judge William Joseph Martinez. The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) DaVita deliberately directed patients into unnecessary insurance plans to maximize profits; (2) the Company was using the American Kidney Fund (“AKF”), a third party charitable 501(c)(3) payor, as a vehicle to facilitate these improper practices; (3) consequentially, DaVita’s revenues and profits were illegally obtained; (4) consequentially, DaVita lacked effective internal controls over financial reporting; and (5) as a result, the Company’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis. Specifically, on August 18, 2016, The Centers for Medicare & Medicaid Services issued a public request for information regarding the alleged steering of Medicare and Medicaid beneficiaries into other plans in order to earn higher reimbursement rates.  Then, on October 23, 2016, the St. Louis Post published an article which directly accused DaVita of steering clients to private insurers and utilizing its own money to pay for health insurance premiums through the AKF.  Lastly, on January 6, 2017, The Wall Street Journal reported, among other things, that investigators from the U.S. Department of Justice “are probing a controversial arrangement under which kidney-care companies support charitable efforts to help patients pay health-insurance premiums, according to disclosures from major dialysis providers.”  As a result of these disclosures, shares of DaVita significantly decline, causing harm to investors. Request more information now by clicking here: www.faruqilaw.com/DVA. There is no cost or obligation to you. Take Action You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected].  Faruqi & Faruqi, LLP also encourages anyone with information regarding DaVita’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. 

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.


Read more...
Deadline Reminder for DaVita Inc. Shareholders – DVA

RADNOR, Pa., March 24, 2017 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP reminds DaVita Inc.   (:DVA) (“DaVita” or the “Company”) shareholders that a class action lawsuit has been filed in the United States District Court for the District of Colorado on behalf of purchasers of DaVita’s securities between August 5, 2015 and October 21, 2016, inclusive (the “Class Period”). 
DEADLINE REMINDER: DaVita shareholders may, no later than April 3, 2017, petition the Court to be appointed as a lead plaintiff representative of the class.  For additional information or to learn how to participate in this action please visit https://www.ktmc.com/new-cases/davita-inc#join. Shareholders who wish to discuss their legal rights or interests with respect to this action are encouraged to contact Kessler Topaz Meltzer & Check (Darren J. Check, Esq., D. Seamus Kaskela, Esq. or Adrienne O. Bell, Esq.) at (888) 299 – 7706 or (610) 667 – 7706, or via e-mail at [email protected]. DaVita provides kidney dialysis services for patients suffering from chronic kidney failure or end-stage renal disease. At relevant times, DaVita made contributions to the American Kidney Fund (“AKF”), a purported charitable foundation that provides financial assistance toward patients’ health insurance premiums. The shareholder class action complaint alleges that DaVita and certain of its executive officers made a series of materially false and misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects to investors during the Class Period, including the following: (1) that the Company and its senior executives purposefully steered patients into unnecessary insurance plans in order to maximize profits; (2) that the Company was using AKF as a vehicle to facilitate these improper practices; (3) that, as a result, DaVita’s revenues and profits were illegally obtained; and (4) that DaVita lacked effective internal controls over financial reporting.  The complaint further alleges that, as a result of the foregoing, the defendants’ statements about DaVita’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis. On August 18, 2016, The Centers for Medicare & Medicaid Services issued a public request for information regarding the alleged steering of Medicare and Medicaid beneficiaries into other plans in order to earn higher reimbursement rates. Following this news, shares of the Company’s stock declined $3.17 per share, or 4.7%, to close on August 19, 2016 at $64.48 per share. Then, on October 23, 2016, the St. Louis Post published an article entitled “DaVita encouraged some low-income patients to enroll in commercial plans” which directly accused DaVita of steering clients to private insurers and utilizing its own money to pay for health insurance premiums through the AKF.  Following this news, shares of the Company’s stock declined an additional $2.86 per share, or 4.7%, to close on October 24, 2016 at $58.10 per share. Subsequently, on January 6, 2017, The Wall Street Journal reported that investigators from the U.S. Department of Justice “are probing a controversial arrangement under which kidney-care companies support charitable efforts to help patients pay health-insurance premiums, according to disclosures from major dialysis providers.” Additionally, the article reported that the “Boston U.S. attorney’s office has subpoenaed DaVita Inc. … seeking ‘the production of information related to charitable premium assistance.’” DaVita shareholders may, no later than April 3, 2017, petition the Court to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check or other counsel, or may choose to do nothing and remain an absent class member.  A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation.  In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class in the action.  Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.  For additional information, or to learn how to participate in this action, please visit https://www.ktmc.com/new-cases/davita-inc#join. Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country.  Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world.  The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars).  The complaint in this action was not filed by Kessler Topaz Meltzer & Check.  For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com
CONTACT:

Kessler Topaz Meltzer & Check, LLP
Darren J. Check, Esq.
D. Seamus Kaskela, Esq.
Adrienne O. Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(888) 299-7706
(610) 667-7706
[email protected]

Read more...
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of DaVita Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 3, 2017 – DVA

NEW YORK, March 22, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of DaVita Inc. (“DaVita”) (:DVA) between August 5, 2015 and October 21, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of Colorado. To get more information go to: http://www.zlk.com/pslra/davita-inc or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you. The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into needless insurance plans to maximize profits; (2) DaVita was using American Kidney Fund to facilitate these inappropriate practices; (3) therefore DaVita’s revenues and profits were illegally acquired; (4) as a result, DaVita lacked effective internal controls over financial reporting. On January 6, 2017, the Wall Street Journal published an article revealing that DaVita had received subpoenas from federal prosecutors seeking “the production of information related to charitable premium assistance” in connection with DaVita’s ties to the American Kidney Fund, a charity that helps patients pay for kidney dialysis. If you suffered a loss in DaVita you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:   
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Read more...

Ratios

vs
industry
vs
history
PE Ratio 10.60
DVA's PE Ratio is ranked higher than
81% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. DVA: 10.60 )
Ranked among companies with meaningful PE Ratio only.
DVA' s PE Ratio Range Over the Past 10 Years
Min: 10.52  Med: 18.45 Max: 58.72
Current: 10.6
10.52
58.72
Forward PE Ratio 18.25
DVA's Forward PE Ratio is ranked higher than
54% of the 108 Companies
in the Global Medical Care industry.

( Industry Median: 18.73 vs. DVA: 18.25 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 10.60
DVA's PE Ratio without NRI is ranked higher than
82% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 28.00 vs. DVA: 10.60 )
Ranked among companies with meaningful PE Ratio without NRI only.
DVA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.52  Med: 18.41 Max: 58.72
Current: 10.6
10.52
58.72
Price-to-Owner-Earnings 7.36
DVA's Price-to-Owner-Earnings is ranked higher than
85% of the 96 Companies
in the Global Medical Care industry.

( Industry Median: 27.48 vs. DVA: 7.36 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DVA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.31  Med: 16.49 Max: 668.7
Current: 7.36
7.31
668.7
PB Ratio 2.45
DVA's PB Ratio is ranked lower than
53% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 2.65 vs. DVA: 2.45 )
Ranked among companies with meaningful PB Ratio only.
DVA' s PB Ratio Range Over the Past 10 Years
Min: 2.25  Med: 3.22 Max: 5.73
Current: 2.45
2.25
5.73
PS Ratio 0.88
DVA's PS Ratio is ranked higher than
67% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.57 vs. DVA: 0.88 )
Ranked among companies with meaningful PS Ratio only.
DVA' s PS Ratio Range Over the Past 10 Years
Min: 0.77  Med: 1.15 Max: 1.46
Current: 0.88
0.77
1.46
Price-to-Free-Cash-Flow 8.48
DVA's Price-to-Free-Cash-Flow is ranked higher than
78% of the 106 Companies
in the Global Medical Care industry.

( Industry Median: 23.72 vs. DVA: 8.48 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DVA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.51  Med: 15.78 Max: 42.42
Current: 8.48
7.51
42.42
Price-to-Operating-Cash-Flow 5.42
DVA's Price-to-Operating-Cash-Flow is ranked higher than
81% of the 154 Companies
in the Global Medical Care industry.

( Industry Median: 14.15 vs. DVA: 5.42 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DVA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.2  Med: 9.03 Max: 15.89
Current: 5.42
5.2
15.89
EV-to-EBIT 8.27
DVA's EV-to-EBIT is ranked higher than
96% of the 292 Companies
in the Global Medical Care industry.

( Industry Median: 18.39 vs. DVA: 8.27 )
Ranked among companies with meaningful EV-to-EBIT only.
DVA' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 12 Max: 20.3
Current: 8.27
6.8
20.3
EV-to-EBITDA 6.34
DVA's EV-to-EBITDA is ranked higher than
94% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 13.46 vs. DVA: 6.34 )
Ranked among companies with meaningful EV-to-EBITDA only.
DVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.5  Med: 9.4 Max: 14.4
Current: 6.34
5.5
14.4
PEG Ratio 1.30
DVA's PEG Ratio is ranked higher than
68% of the 94 Companies
in the Global Medical Care industry.

( Industry Median: 3.11 vs. DVA: 1.30 )
Ranked among companies with meaningful PEG Ratio only.
DVA' s PEG Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.42 Max: 5.59
Current: 1.3
0.4
5.59
Shiller PE Ratio 22.98
DVA's Shiller PE Ratio is ranked higher than
58% of the 45 Companies
in the Global Medical Care industry.

( Industry Median: 28.31 vs. DVA: 22.98 )
Ranked among companies with meaningful Shiller PE Ratio only.
DVA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.78  Med: 29.99 Max: 62.67
Current: 22.98
19.78
62.67
Current Ratio 1.64
DVA's Current Ratio is ranked higher than
57% of the 244 Companies
in the Global Medical Care industry.

( Industry Median: 1.30 vs. DVA: 1.64 )
Ranked among companies with meaningful Current Ratio only.
DVA' s Current Ratio Range Over the Past 10 Years
Min: 0.39  Med: 1.86 Max: 5.97
Current: 1.64
0.39
5.97
Quick Ratio 1.57
DVA's Quick Ratio is ranked higher than
60% of the 244 Companies
in the Global Medical Care industry.

( Industry Median: 1.18 vs. DVA: 1.57 )
Ranked among companies with meaningful Quick Ratio only.
DVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.37  Med: 1.8 Max: 5.97
Current: 1.57
0.37
5.97
Days Inventory 6.29
DVA's Days Inventory is ranked higher than
79% of the 192 Companies
in the Global Medical Care industry.

( Industry Median: 16.88 vs. DVA: 6.29 )
Ranked among companies with meaningful Days Inventory only.
DVA' s Days Inventory Range Over the Past 10 Years
Min: 3.72  Med: 6 Max: 8.61
Current: 6.29
3.72
8.61
Days Sales Outstanding 46.68
DVA's Days Sales Outstanding is ranked lower than
59% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 40.40 vs. DVA: 46.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
DVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.53  Med: 62.54 Max: 69.35
Current: 46.68
43.53
69.35
Days Payable 15.73
DVA's Days Payable is ranked lower than
78% of the 162 Companies
in the Global Medical Care industry.

( Industry Median: 40.41 vs. DVA: 15.73 )
Ranked among companies with meaningful Days Payable only.
DVA' s Days Payable Range Over the Past 10 Years
Min: 14.92  Med: 19.24 Max: 27.07
Current: 15.73
14.92
27.07

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.00
DVA's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 130 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. DVA: 3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -58.4  Med: -0.8 Max: 9.3
Current: 3
-58.4
9.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.70
DVA's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
87% of the 89 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. DVA: 0.70 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DVA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.69  Med: 1.16 Max: 13.33
Current: 0.7
0.69
13.33
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.88
DVA's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
75% of the 32 Companies
in the Global Medical Care industry.

( Industry Median: 1.81 vs. DVA: 0.88 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.76
DVA's Price-to-Median-PS-Value is ranked higher than
75% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 1.04 vs. DVA: 0.76 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.16  Med: 1.08 Max: 5.28
Current: 0.76
0.16
5.28
Price-to-Peter-Lynch-Fair-Value 1.23
DVA's Price-to-Peter-Lynch-Fair-Value is ranked lower than
55% of the 47 Companies
in the Global Medical Care industry.

( Industry Median: 2.13 vs. DVA: 1.23 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
DVA' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.46  Med: 1.3 Max: 8.16
Current: 1.23
0.46
8.16
Earnings Yield (Greenblatt) % 12.07
DVA's Earnings Yield (Greenblatt) % is ranked higher than
96% of the 334 Companies
in the Global Medical Care industry.

( Industry Median: 4.98 vs. DVA: 12.07 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DVA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.9  Med: 8.4 Max: 14.6
Current: 12.07
4.9
14.6
Forward Rate of Return (Yacktman) % 15.71
DVA's Forward Rate of Return (Yacktman) % is ranked higher than
60% of the 119 Companies
in the Global Medical Care industry.

( Industry Median: 11.19 vs. DVA: 15.71 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
DVA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 12.5  Med: 19.9 Max: 35.4
Current: 15.71
12.5
35.4

More Statistics

Revenue (TTM) (Mil) $14,861
EPS (TTM) $ 6.12
Beta1.08
Short Percentage of Float2.62%
52-Week Range $54.50 - 78.77
Shares Outstanding (Mil)194.60

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 15,279 16,231
EPS ($) 3.58 3.93
EPS without NRI ($) 3.58 3.93
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.34%
Dividends per Share ($)
» More Articles for DVA

Headlines

Articles On GuruFocus.com
DaVita Celebrates Military Appreciation Month May 25 2017 
DaVita Kidney Care Welcomes Eric Severson as Chief People Officer May 24 2017 
DaVita Honors Commitment to Healthy Living during Employee Health and Fitness Month May 23 2017 
DaVita Medical Insights: Launching a Podcast for Physicians, by Physicians May 23 2017 
DaVita Reports on 2016 Corporate Social Responsibility and Innovation May 22 2017 
Paul Tudor Jones’ Top 4 Health Care Buys May 18 2017 
DaVita and Bridge of Life Partner to Provide Health Screenings and Access to Health Care in Haiti an May 16 2017 
DaVita Helps Raise Awareness of Mental Illness During Mental Health Month May 12 2017 
DaVita Acquires Purity Dialysis May 08 2017 
DaVita Celebrates National Nurses Week May 08 2017 

More From Other Websites
DaVita acquires Polish dialysis company May 25 2017
These 5 Healthcare Stocks Are Undervalued May 25 2017
DaVita Celebrates Military Appreciation Month May 25 2017
DaVita Kidney Care Welcomes Eric Severson as Chief People Officer May 24 2017
DaVita Medical Insights: Launching a Podcast for Physicians, by Physicians May 23 2017
DaVita Honors Commitment to Healthy Living during Employee Health and Fitness Month May 23 2017
DaVita Reports on 2016 Corporate Social Responsibility and Innovation May 22 2017
DaVita Clinical Research Celebrates International Clinical Trials Day May 19 2017
Paul Tudor Jones' Top 4 Health Care Buys May 18 2017
Dr. George R. Aronoff Joins DaVita Kidney Care Physician Leadership Team May 18 2017
DaVita Supports World Hypertension Day May 17 2017
DaVita and Bridge of Life Partner to Provide Health Screenings and Access to Health Care in Haiti... May 16 2017
John Oliver tackled a healthcare story last night, and it was a thing of beauty May 15 2017
John Oliver ripped into a CEO who proudly compared his healthcare business to Taco Bell May 15 2017
DaVita Helps Raise Awareness of Mental Illness During Mental Health Month May 12 2017
Advisory Board alum raises $5 million for his kidney care startup May 12 2017
Business-backed open primary elections are about to become Colorado law May 10 2017
Edited Transcript of DVA earnings conference call or presentation 2-May-17 9:00pm GMT May 09 2017
The 3 Best Buffett Stocks for Retirees May 09 2017
DaVita Acquires Purity Dialysis May 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)